Amazon removes eye drops from website after FDA warning
Click Here to Manage Email Alerts
After receiving a warning letter from the FDA, the online retailer Amazon removed seven unregulated eye drop products from its website.
In a letter addressed to Andrew Jassy, CEO of Amazon, the FDA wrote, “These products are especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.”
Upon removal of the products, Amazon released a statement saying, “Safety is a top priority at Amazon. We require all products offered in our store to comply with applicable laws and regulations,” the Washington Post reported.
The seven unapproved products listed in the FDA warning letter are Similasan Pink Eye Relief, The Goodbye Company Pink Eye, Can-C Eye Drops, Optique 1 Eye Drops, OculuMed Eye Drops, TRP Natural Eyes Floaters Relief and Manzanilla Sophia Chamomile Herbal Eye Drops.
According to the letter, Amazon’s distribution of these drugs was in violation of sections 301(d) and 505(A) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. 355(a).
References:
- Amazon removes 7 eye-drop products after FDA warning. https://www.washingtonpost.com/business/2023/11/15/eye-drop-amazon-fda-warning/. Accessed Nov. 17, 2023.
- Warning letter: Amazon.com Inc. MARCS-CMS 665460 – November 13, 2023. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amazoncom-inc-665460-11132023. Accessed Nov. 17, 2023.
Read more about
Click Here to Manage Email Alerts